This multi-center observational study investigates the association between incretin-based drugs and the risk of heart failure (HF) in patients with type 2 diabetes. Given the increasing prevalence of diabetes and the significant market for anti-diabetic medications, understanding the cardiovascular safety profile of incretin-based therapies is critical for market positioning. The results may influence prescribing practices and regulatory scrutiny, potentially impacting the competitive landscape among diabetes treatments. Companies involved in the development of incretin-based therapies may need to reassess their risk management strategies and market communications based on the findings of this study.